Synergistic effect of α-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment

Journal of Diabetes Investigation

Volumn 2, Issue 3, 2011, Pages 200-203

  Horikawa, Yukio ^a   Enya, Mayumi ^a   Iizuka, Katsumi ^a   Chen, Gui Ying ^a   Kawachi, Shin Ichi ^a   Suwa, Tetsuya ^a   Takeda, Jun ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

Glucagon like peptide 1; Insulin; Postprandial hyperglycemia

Indexed keywords

ACARBOSE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; MALTOSE; MIGLITOL; SITAGLIPTIN; VOGLIBOSE;

ANIMAL EXPERIMENT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HORMONE BLOOD LEVEL; INSULIN BLOOD LEVEL; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 79961082493     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00081.x     Document Type: Article

References (13)

1. Chiasson JL, Josse RG, Gomis R, et al. Stop-NIDDM Trail Research Group Acarbose prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077.
2. Narita T, Katsuura Y, Sato T, et al. Miglitol induces prolonged and enhanced glucagons-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 2009; 26: 187-188.
3. Esposito K, Ciotola M, Carleo D, et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 1345- 1350.
4. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59: 1030-1037.
5. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132-140.
6. Yamazaki K, Inoue T, Yasuda N, et al. Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice. J Pharmacol Sci 2007; 104: 29-38.
7. Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab 2010; 12: 224-233.
8. Mita T, Otsuka A, Azuma K, et al. Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 2007; 358: 679-685.
9. Fukaya N, Mochizuki K, Tanaka Y, et al. The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats. Eur J Pharmacol 2009; 624: 51-57.
10. McLaughlin T, Abbasi F, Lamendola C, et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002; 106: 2908-2912.
11. Lee A, Patrick P, Wishart J, et al. The effects of miglitol on glucagons-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 2002; 4: 329-335.
12. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
13. Qualmann C, Nauck MA, Holst JJ, et al. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995; 30: 892-896.